McIntosh M. W. et al. [35] evaluated the usefulness of a composite marker (CM), a combination of CA125 and SMR (soluble mesothelin related), in sera from 52 women with ovarian cancer, 43 women with benign ovarian tumours and 220 healthy women. This evidence concerns the gene MSLN and ovarian carcinoma.